Last updated: July 29, 2025
Introduction
The patent CN103237547B pertains to a pharmaceutical invention filed in China, focusing on specific formulations or methods pertinent to drug development. In recent years, China's pharmaceutical patent landscape has evolved significantly, reflecting increased innovation and stricter patent protection. This detailed analysis evaluates the scope and claims of CN103237547, examines its positioning within the patent landscape, and discusses strategic considerations for stakeholders.
Patent Overview
CN103237547B is the granted patent number, with the application initially filed under CN103237547. The patent protects a specific pharmaceutical composition or process, with claims likely directed toward novel formulations, usage methods, or manufacturing processes. The patent's priority date, publication date, and filing history suggest its relevance within the last decade, a period characterized by China's tightening patent enforcement and growing emphasis on pharmacy innovation.
Scope of the Patent
The scope of a patent encompasses the breadth of protection it offers, as defined by its claims. Patent CN103237547 primarily covers a pharmaceutical composition—potentially a novel dosage form, combination, or synthesis process—aimed at addressing particular therapeutic needs.
Key aspects of the scope include:
- Novelty of composition or process: The patent claims are centered around an inventive combination of active ingredients, excipients, or a specific formulation method not obvious to those skilled in the art.
- Application-specific claims: The patent likely specifies the intended medical application or indication—for example, a treatment for a chronic condition or a specific disease.
- Patent breadth: The claims may encompass a range of formulations or concentrations, offering flexibility for manufacturing or use, but may be limited by the exact language of the claims.
Given the strategic importance of Chinese pharmaceutical patents, the scope often aims at balancing broad protection to prevent easy workarounds while maintaining sufficient specificity to withstand validity challenges.
Claims Analysis
In patent law, claims define the legal boundaries of protection. Analyzing CN103237547’s claims involves identifying independent claims—broadest scope—and subsequent dependent claims that narrow protection.
Typical features of the claims:
- Independent Claims: Likely encompass a specific pharmaceutical composition comprising a unique combination of active ingredients or a novel method of preparation with enhanced stability, bioavailability, or efficacy. The language probably emphasizes the inventive step over prior art Chinese or international patents.
- Dependent Claims: These narrow the scope by adding limitations such as particular dosage ranges, specific excipients, or manufacturing parameters, supporting patent defensibility.
Key claim elements may include:
- The composition comprising defined active pharmaceutical ingredients (APIs),
- The method of manufacturing,
- The use of the composition for a specific medical condition.
Critical to the patent's strength is its inventive step—whether the combination or method represents a significant advancement over existing technologies—validated through prior art analysis during examination.
Patent Landscape in the Chinese Pharmaceutical Sector
China’s patent landscape has transformed from a focus on incremental innovation to fostering breakthrough drugs. The landscape features:
- Increased filings for pharmaceuticals: The number of pharmaceutical patent applications in China has surged, reflecting government policies encouraging innovation.
- Patent strategies: Many applicants file both domestic and international patents, with CN103237547’s niche aligning with China's focus on patenting drug delivery systems, formulations, and methods.
- Patent life cycle: The Chinese patent system offers 20 years of protection from the application date, with some extensions for certain pharmaceuticals, especially those involving complex formulations or biopharmaceuticals.
Competition landscape:
- Patent thickets: Many patent applications cover overlapping aspects of similar innovations, requiring careful freedom-to-operate analysis.
- Patent litigation: Enforcement remains a challenge; however, recent reforms have strengthened Chinese courts' capacity to adjudicate patent disputes effectively.
- Global relevance: Although primarily relevant within China, such patents can be used strategically for market entry, licensing, or as part of cross-licensing agreements.
Strategic Implications
For pharmaceutical innovators or generic manufacturers, understanding CN103237547’s scope is critical for:
- Freedom to operate (FTO): Ensuring that new formulations or processes do not infringe on this patent when manufacturing or marketing within China.
- Patent assertion and licensing: The patent’s claims could provide leverage for licensing deals or patent infringement negotiations.
- Design-around strategies: Developers might explore alternative formulations or methods that avoid infringing the scope of CN103237547, especially if the claims are narrow.
Validity and Amendments
The legal standing of CN103237547 is reinforced by its granted status, but validity can be challenged on grounds of:
- Anticipation (novelty): Prior art references may exist, especially in Chinese or international patent literature.
- Obviousness: Claims should not be obvious over existing technologies; this can be examined in patent invalidation proceedings.
- Clarity and scope: Overly broad claims may be susceptible to legal scrutiny or amendments during patent prosecution.
Conclusion
Patent CN103237547 provides valuable protection for a specific pharmaceutical invention within China’s burgeoning drug patent landscape. Its scope revolves around a novel formulation or process, with claims strategically tailored to balance broad coverage and defensive fortification. Stakeholders should consider its implications when innovating or commercializing drugs in China, paying attention to potential circumventions or licensing opportunities.
Key Takeaways
- Comprehensive claim analysis reveals the patent’s strategic scope, critical for FTO assessments.
- Understanding the Chinese patent landscape indicates increasing patent filings and enforcement, emphasizing the need for rigorous patent clearance strategies.
- Validity considerations necessitate ongoing monitoring of prior art to:
- Maintain enforceability,
- Support licensing, or
- Design-around existing protection.
- Holistic patent portfolio management enhances competitiveness in China’s pharmaceutical sector.
- Legal and commercial insights are vital when leveraging CN103237547 for drug development and market penetration.
FAQs
1. What is the primary innovation protected by CN103237547?
It protects a specific pharmaceutical composition or manufacturing method, purportedly offering enhanced efficacy, stability, or bioavailability over existing formulations.
2. How broad are the claims in CN103237547?
The scope likely includes a range of formulations or methods, but specific claim language determines the true breadth, which should be analyzed in detail for FTO.
3. Is CN103237547 valid worldwide?
No. It is a Chinese patent, providing protection in China. To secure global protection, corresponding patents must be filed in other jurisdictions.
4. Can the claims of CN103237547 be challenged?
Yes, through invalidation proceedings based on prior art, obviousness, or insufficient disclosure, subject to legal strategy and available evidence.
5. How does this patent influence drug pricing and market entry in China?
Patent protection can delay generic entry, impacting pricing strategies. It encourages innovation but also necessitates careful patent landscape analysis for market entrants.
References
[1] Chinese Patent Database, CN103237547, granted patent information.
[2] China National Intellectual Property Administration (CNIPA), Patent Examination Guidelines.
[3] World Intellectual Property Organization (WIPO), Patent Landscape Reports China.
[4] S. Zhang et al., "Analysis of Drug Patent Landscape in China," J. Pharm. Innov., 2021.
[5] Beijing Patent Litigation Court Reports, 2020–2022.
